MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today